By Karen Roman
Medical imaging company Nano-X Imaging Ltd. (Nasdaq: NNOX) said it received clearance from the Food and Drug Administration for HealthCCSng V2.0, an upgraded version of its advanced AI cardiac solution HealthCCSng.
HealthCCSng assesses coronary artery calcium levels as a way of predicting future cardiovascular incidents, it said in a statement.
The improved HealthCCSng V2.0 has additional ‘zero calcium’ categorization and creates a numerical calcium score, among other features, Nanox said.
“The AI cardiac solution helps to bridge the divide between radiology and cardiology, two medical specialties that often use different terms and descriptions to assess imaging data,” said Erez Meltzer, Nanox’s CEO.
Contact:
Editor@executives-edge.com
